Glaukos Corporation   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: San Clemente CA United States (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2009
NCT00913029
First Marketed Drug
2016
riboflavin
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

GLAUKOS | Glaukos Corporation

Active Ingredients

Marketed Drugs (1)

Key: Glaukos Corporation (0) Acquired (1)

riboflavin (2016)

Drugs in Phase 4 Trials (6)

Key: Glaukos Corporation (5) Acquired (1)

latanoprost (xalatan) (1 trial)

riboflavin (6 trials)

timolol (blocadren) (4 trials)

tobramycin (nebcin) (1 trial)

travoprost (travatan) (7 trials)

urea (1 trial)

Drugs in Phase 3 Trials (1)

Key: Glaukos Corporation (0) Acquired (1)

ribavirin (virazole) (3 trials)

Drugs in Phase 2 Trials (1)

pilocarpine (ocusert) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Eye Diseases (Phase 4)

Glaucoma (Phase 4)

Glaucoma, Open-Angle (Phase 4)

Hypertension (Phase 4)

Ocular Hypertension (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 8